Turnaround For Spectrum’s Poziotinib As Phase II Cohort 2 Meets Endpoint

 
• By Jung Won Shin

Spectrum is set to discuss NDA submission plans with the US FDA after unveiling positive top line results from Cohort 2 of the Phase II ZENITH20 study with poziotinib, in pretreated NSCLC patients with HER2 exon 20 insertion mutations. The drug, licensed from Hanmi, failed in the Cohort 1 part of the trial earlier this year.

Digital illustration of Cancer cell in colour background
Spectrum To Discuss Poziotinib With FDA To Determine Path Forward • Source: Shutterstock

More from South Korea

More from Focus On Asia